Drugs / DCBY02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05496595 | Oct 2022 → Feb 2024 | — | DynamiCure Biotechnology | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-08-22 | DynamiCure Biotechnology | Regulatory DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development dynamicure.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-08 | DynamiCure Biotechnology | DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers dynamicure.com ↗ |
| 2022-08-22 | DynamiCure Biotechnology | DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development dynamicure.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCBY02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496595 ↗ |
| Modality | Monoclonal antibody | “anti-CD93 mAb (DCBY02)” NCT05496595 ↗ |
| Route | Intravenous | “administered as a single intravenous (IV) infusion” NCT05496595 ↗ |
| Target | CD93 | “binds to CD93” NCT05496595 ↗ |